News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Acrux.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: US FDA happy to review anal fissure drug; gives green light to Clarity’s Phase 3 trial
Health & Biotech
ASX Health Stocks: Polynovo surges on sales; Pacific Edge wiped out 60pc after losing Medicare coverage
Health & Biotech
ASX Health Stocks: Acrux and Lumos await potential approvals from the US FDA
Health & Biotech
ASX Health Stocks: Antisense says ATL1102 could be effective in rare genetic muscle disease
Health & Biotech
Check Up: ASX biotech comes alive as health stocks tackle international markets
Health & Biotech
ASX Health Stocks: HeraMed jumps 11pc on survey results, while Acrux seeks FDA approval for acne gel
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
ASX Health Stocks: Acrux flags testosterone solution with an armpit application, Clinuvel posts record revenues
Health & Biotech
ScoPo’s Powerplays: Solid earnings for health stocks all round, but price action stays with larger caps
Health & Biotech
ASX Health Stocks: Chimeric gets licence for CAR-T from U-Pen, Acrux gets nod from the FDA
Health & Biotech
The surge and plunge in ASX biotech shows what the FDA giveth, the FDA taketh away
Health & Biotech
ScoPo’s Powerplays: Buying opportunities in a volatile week
Health & Biotech
Check Up: From Moderna’s effective jabs to Patrys’ brain cancer breakthrough
Health & Biotech
Suda Pharma pops 44pc on cap raise; Acrux and other biotechs whet investor appetites
News
Closing Bell: Today’s biggest small cap movers on the ASX
Health & Biotech
Acrux shares gain after FDA approves its toenail fungus treatment
News